AU744824B2 - Improved process for obtaining insulin precursors having correctly bonded cystine bridges - Google Patents

Improved process for obtaining insulin precursors having correctly bonded cystine bridges Download PDF

Info

Publication number
AU744824B2
AU744824B2 AU80763/98A AU8076398A AU744824B2 AU 744824 B2 AU744824 B2 AU 744824B2 AU 80763/98 A AU80763/98 A AU 80763/98A AU 8076398 A AU8076398 A AU 8076398A AU 744824 B2 AU744824 B2 AU 744824B2
Authority
AU
Australia
Prior art keywords
cysteine
amino acid
approximately
insulin
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU80763/98A
Other languages
English (en)
Other versions
AU8076398A (en
Inventor
Reinhold Keller
Franz-Josef Rubroder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of AU8076398A publication Critical patent/AU8076398A/en
Assigned to AVENTIS PHARMA DEUTSCHLAND GMBH reassignment AVENTIS PHARMA DEUTSCHLAND GMBH Amend patent request/document other than specification (104) Assignors: HOECHST MARION ROUSSEL DEUTSCHLAND GMBH
Assigned to AVENTIS PHARMA DEUTSCHLAND GMBH reassignment AVENTIS PHARMA DEUTSCHLAND GMBH Amend patent request/document other than specification (104) Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Application granted granted Critical
Publication of AU744824B2 publication Critical patent/AU744824B2/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request to Amend Deed and Register Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU80763/98A 1997-08-18 1998-08-17 Improved process for obtaining insulin precursors having correctly bonded cystine bridges Expired AU744824B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19735711A DE19735711C2 (de) 1997-08-18 1997-08-18 Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19735711.3 1997-08-18

Publications (2)

Publication Number Publication Date
AU8076398A AU8076398A (en) 1999-02-25
AU744824B2 true AU744824B2 (en) 2002-03-07

Family

ID=7839275

Family Applications (1)

Application Number Title Priority Date Filing Date
AU80763/98A Expired AU744824B2 (en) 1997-08-18 1998-08-17 Improved process for obtaining insulin precursors having correctly bonded cystine bridges

Country Status (20)

Country Link
US (3) US5986048A (cg-RX-API-DMAC7.html)
EP (2) EP0980874B1 (cg-RX-API-DMAC7.html)
JP (1) JP4291900B2 (cg-RX-API-DMAC7.html)
KR (2) KR100537842B1 (cg-RX-API-DMAC7.html)
CN (3) CN1483831B (cg-RX-API-DMAC7.html)
AR (1) AR016821A1 (cg-RX-API-DMAC7.html)
AT (2) ATE217012T1 (cg-RX-API-DMAC7.html)
AU (1) AU744824B2 (cg-RX-API-DMAC7.html)
BR (2) BR9803755A (cg-RX-API-DMAC7.html)
CA (1) CA2245151C (cg-RX-API-DMAC7.html)
CZ (1) CZ295679B6 (cg-RX-API-DMAC7.html)
DE (3) DE19735711C2 (cg-RX-API-DMAC7.html)
DK (2) DK0906918T3 (cg-RX-API-DMAC7.html)
ES (2) ES2177178T3 (cg-RX-API-DMAC7.html)
HU (2) HU228161B1 (cg-RX-API-DMAC7.html)
ID (1) ID20717A (cg-RX-API-DMAC7.html)
PL (1) PL191901B1 (cg-RX-API-DMAC7.html)
PT (2) PT980874E (cg-RX-API-DMAC7.html)
RU (2) RU2205836C2 (cg-RX-API-DMAC7.html)
TR (1) TR199801587A3 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19930676B4 (de) * 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
JP2003530316A (ja) * 1999-12-22 2003-10-14 ノボ ノルディスク アクティーゼルスカブ スクランブルした一本鎖ポリペプチドの抽出的再生法
US20030212248A1 (en) * 2000-07-12 2003-11-13 Furman Thomas Charles Process to increase protein stability
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
DE102004015965A1 (de) * 2004-04-01 2005-10-20 Aventis Pharma Gmbh Verfahren zur Gewinnung von Insulinen durch verbesserte Luftbegasung der Faltung
MY143274A (en) 2005-12-22 2011-04-15 Genentech Inc Recombinant production of heparin binding proteins
CN101506222B (zh) 2006-07-14 2013-10-02 健泰科生物技术公司 重组蛋白的重折叠
EA018715B1 (ru) * 2007-07-03 2013-10-30 Эмджен Инк. Количественное определение белков с использованием сухого веса внутриклеточных телец
RU2451750C2 (ru) * 2007-09-24 2012-05-27 Общество С Ограниченной Ответственностью "Герофарм" Способ получения рекомбинантного с-пептида проинсулина человека
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
WO2009133529A2 (en) * 2008-04-30 2009-11-05 Wockhardt Research Centre Processes for refolding of insulin
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Glp−1アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US12157766B2 (en) * 2012-08-05 2024-12-03 Absci Corporation Cytoplasmic expression system
US10421795B2 (en) 2012-12-17 2019-09-24 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
KR20140106452A (ko) * 2013-02-26 2014-09-03 한미약품 주식회사 신규한 인슐린 아날로그 및 이의 용도
CN103694339B (zh) * 2013-12-04 2017-10-13 珠海联邦制药股份有限公司 一种甘精胰岛素前体的复性方法
US10407483B2 (en) 2014-03-14 2019-09-10 Merck Sharp & Dohme Corp. Purifying insulin using cation exchange and reverse phase chromatography in the presence of an organic modifier and elevated temperature
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
CN104911203A (zh) * 2015-06-30 2015-09-16 成都易胜科生物科技有限公司 一种重组人胰岛素的工业制备方法
WO2017040363A1 (en) 2015-09-02 2017-03-09 Merck Sharp & Dohme Corp. A process for obtaining insulin with correctly formed disulfide bonds
US10689430B2 (en) 2016-05-25 2020-06-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN113773400B (zh) * 2020-06-09 2023-08-18 宁波鲲鹏生物科技有限公司 一种门冬胰岛素衍生物及其应用
CN113773391B (zh) * 2020-06-09 2023-10-20 宁波鲲鹏生物科技有限公司 一种门冬胰岛素的制备方法
CN113773396A (zh) * 2020-06-10 2021-12-10 宁波鲲鹏生物科技有限公司 一种地特胰岛素衍生物及其应用
JP7749397B2 (ja) * 2021-09-30 2025-10-06 キヤノン株式会社 超音波ファントム及び超音波ファントムの製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) * 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DE3501641A1 (de) * 1985-01-19 1986-07-24 Hoechst Ag, 6230 Frankfurt Verfahren zur gewinnung von insulin-vorlaeufern aus reaktionsgemischen, die bei der faltung von insulin-vorlaeufern aus den entsprechenden s-sulfonaten anfallen
IL95495A (en) * 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
RU2045535C1 (ru) * 1991-06-18 1995-10-10 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Способ получения проинсулина человека
SG46612A1 (en) * 1992-12-02 1998-02-20 Hoechst Ag Process for obtaining proinsulin in processing correctly linked cystine bridges
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
RU2081122C1 (ru) * 1994-06-16 1997-06-10 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Способ выделения и очистки инсулина или его биотехнологических предшественников
ATE350053T1 (de) * 1994-12-29 2007-01-15 Ferring Int Ct Sa Herstellung von humaninsulin
DE19735711C2 (de) * 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken

Also Published As

Publication number Publication date
HU0600287D0 (en) 2006-05-29
CN1209437A (zh) 1999-03-03
PT906918E (pt) 2002-10-31
JP4291900B2 (ja) 2009-07-08
KR100574580B1 (ko) 2006-04-28
HU228161B1 (en) 2013-01-28
ES2176870T3 (es) 2002-12-01
PL191901B1 (pl) 2006-07-31
ES2177178T3 (es) 2002-12-01
KR100537842B1 (ko) 2006-03-23
TR199801587A2 (xx) 1999-03-22
ATE217012T1 (de) 2002-05-15
EP0980874B1 (de) 2002-05-02
JPH11130798A (ja) 1999-05-18
US6380355B1 (en) 2002-04-30
DE59803985D1 (de) 2002-06-06
AU8076398A (en) 1999-02-25
ATE217636T1 (de) 2002-06-15
KR20050067371A (ko) 2005-07-01
EP0980874A1 (de) 2000-02-23
US6727346B2 (en) 2004-04-27
EP0906918B1 (de) 2002-05-15
US5986048A (en) 1999-11-16
CN1483831A (zh) 2004-03-24
PT980874E (pt) 2002-10-31
HK1119449A1 (en) 2009-03-06
TR199801587A3 (tr) 1999-03-22
CZ295679B6 (cs) 2005-09-14
CN101186940A (zh) 2008-05-28
KR19990023651A (ko) 1999-03-25
BRPI9816233B8 (pt) 2021-05-25
EP0906918A3 (de) 1999-08-11
CN1483831B (zh) 2012-06-13
HUP9801886A2 (hu) 1999-01-28
RU2302882C2 (ru) 2007-07-20
PL328108A1 (en) 1999-03-01
HK1018464A1 (en) 1999-12-24
US20020156234A1 (en) 2002-10-24
CA2245151A1 (en) 1999-02-18
RU2205836C2 (ru) 2003-06-10
HK1061870A1 (en) 2004-10-08
HU9801886D0 (en) 1998-10-28
DE59804121D1 (de) 2002-06-20
BR9803755A (pt) 2000-03-28
CA2245151C (en) 2009-10-06
HUP9801886A3 (en) 1999-06-28
CN101186940B (zh) 2012-02-08
CN1132845C (zh) 2003-12-31
BRPI9816233B1 (pt) 2016-09-27
DK0906918T3 (da) 2002-09-09
EP0906918A2 (de) 1999-04-07
DE19735711C2 (de) 2001-04-26
HU228203B1 (en) 2013-01-28
CZ259898A3 (cs) 1999-03-17
AR016821A1 (es) 2001-08-01
ID20717A (id) 1999-02-18
DE19735711A1 (de) 1999-02-25
DK0980874T3 (da) 2002-08-19

Similar Documents

Publication Publication Date Title
CA2245151C (en) Improved process for obtaining insulin precursors having correctly bonded cystine bridges
CA2142780C (en) Process for obtaining insulin having correctly linked cystine bridges
AU662083B2 (en) Process for obtaining proinsulin possessing correctly linked cystine bridges
HU215582B (hu) Eljárás humán inzulin N-terminális szekvenciájának enzimes eltávolítására
HUT63457A (en) Process for producing triarginine insulins
IE841995L (en) Preparing an insulin derivative
US7659363B2 (en) Process for the preparation of insulin or an insulin derivative in the presence of oxygen
AU644032B2 (en) Process for the enzymatic preparation of GRF(1-44) amide
EP0570244B1 (en) Process for preparing peptides having a C-terminal proline amide
NZ243229A (en) Insulin analogue consisting of two crosslinked amino acid sequences, pharmaceutical compositions
MXPA98006666A (en) Improved procedure for the obtaining of insulin precursors with cistina bridges correctly uni
HK1119449B (en) Process for obtaining insulin or insulin derivatives having correctly bonded cystine bridges
HK1061870B (en) Improved process for obtaining insulin precursors having correctly bonded cystine bridges
HK1010457B (en) Process to obtain insulin with correct cystin bridges
HK1003839B (en) Process for preparing peptides having a c-terminal proline amide

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: ON=AVENTIS PHARMA DEUTSCHLAND GMBH; FT=FORMER NAME

TC Change of applicant's name (sec. 104)

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH

Free format text: FORMER NAME: HOECHST MARION ROUSSEL DEUTSCHLAND GMBH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired